Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Blog Pricing

Jessica Mendoza

đŸ‘€ Speaker
6628 total appearances

Appearances Over Time

Podcast Appearances

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Yeah.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Yeah.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

We asked the foundation yesterday if Sorensen still welcomes the competition. The foundation had no further comment. In the meantime, both Novo and Lilly are pressing on with the next big thing. Promises of more effective injectables, a more convenient pill, and even more weight loss.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

We asked the foundation yesterday if Sorensen still welcomes the competition. The foundation had no further comment. In the meantime, both Novo and Lilly are pressing on with the next big thing. Promises of more effective injectables, a more convenient pill, and even more weight loss.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

We asked the foundation yesterday if Sorensen still welcomes the competition. The foundation had no further comment. In the meantime, both Novo and Lilly are pressing on with the next big thing. Promises of more effective injectables, a more convenient pill, and even more weight loss.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

What does this leadership shakeup sort of say about the pharmaceutical industry right now, like especially in the weight loss space?

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

What does this leadership shakeup sort of say about the pharmaceutical industry right now, like especially in the weight loss space?

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

What does this leadership shakeup sort of say about the pharmaceutical industry right now, like especially in the weight loss space?

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Right.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Right.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Right.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

That's all for today, Wednesday, May 21st. The Journal is a co-production of Spotify and The Wall Street Journal. Additional reporting in this episode from Dominic Chopping. Additional production from Adrienne Murray Nielsen. Thanks for listening. See you tomorrow.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

That's all for today, Wednesday, May 21st. The Journal is a co-production of Spotify and The Wall Street Journal. Additional reporting in this episode from Dominic Chopping. Additional production from Adrienne Murray Nielsen. Thanks for listening. See you tomorrow.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

That's all for today, Wednesday, May 21st. The Journal is a co-production of Spotify and The Wall Street Journal. Additional reporting in this episode from Dominic Chopping. Additional production from Adrienne Murray Nielsen. Thanks for listening. See you tomorrow.

The Journal.
Can the GOP Unite Around Trump’s ‘Big, Beautiful Bill’?

For months, President Donald Trump has been promoting what he calls his big, beautiful bill.

The Journal.
Can the GOP Unite Around Trump’s ‘Big, Beautiful Bill’?

For months, President Donald Trump has been promoting what he calls his big, beautiful bill.

The Journal.
Can the GOP Unite Around Trump’s ‘Big, Beautiful Bill’?

For months, President Donald Trump has been promoting what he calls his big, beautiful bill.

The Journal.
Can the GOP Unite Around Trump’s ‘Big, Beautiful Bill’?

How many pages is this bill?

The Journal.
Can the GOP Unite Around Trump’s ‘Big, Beautiful Bill’?

How many pages is this bill?

The Journal.
Can the GOP Unite Around Trump’s ‘Big, Beautiful Bill’?

How many pages is this bill?